The company is commercializing a genome-wide sequencing method called MRDetect, developed by researchers at the New York Genome Center and Weill Cornell Medicine.
With $2.5 million in initial philanthropy funding, the consortium plans to launch several research projects and establish a data commons for storing and sharing results.
The method allows for the annotation of cells by their genotype and capture of single-cell transcriptomes, even when the cells aren't morphologically distinct.
A New York Genome Consortium-led team plans retrospective and prospective analyses on very rare cancers in the hopes of improving treatment options available for patients.
